The discovery of a new potentially relevant oncogenic event in lung cancer, the EML4-ALK translocation, and the development of ALK inhibitors with promising results in preclinical models and randomized clinical trials provides the rationale for the comprehensive characterization of ALK abnormalities in patients with other solid tumors, such as CRC [10], [11]. The gene discussed is ALK; the disease is colorectal carcinoma.